Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice (Q34131354)

31 July 2017

1 reference

title

Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice (English)

1 reference

31 July 2017

1 reference

personalized medicine

1 reference

1

Alessio Squassina

1 reference

31 July 2017

8

Maria Del Zompo

0 references

Mirko Manchia

2

object named as

Mirko Manchia

0 references

George P Patrinos

9

object named as

George P Patrinos

1 reference

31 July 2017

Konstantinos Mitropoulos

7

object named as

Konstantinos Mitropoulos

1 reference

31 July 2017

Mirko Manchia

2

1 reference

31 July 2017

Vangelis G Manolopoulos

3

1 reference

31 July 2017

Mehmet Artac

4

1 reference

31 July 2017

Christina Lappa-Manakou

5

1 reference

31 July 2017

Sophia Karkabouna

6

1 reference

31 July 2017

1 August 2010

1 reference

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

1149-1167

1 reference

31 July 2017

8

1 reference

Adverse drug reactions in hospitals: a narrative review

31 July 2017

1 reference

Pharmacogenomics and therapeutics of hemoglobinopathies

21 January 2018

1 reference

Adverse drug reactions: role of pharmacogenomics

21 January 2018

1 reference

Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice

21 January 2018

1 reference

Pharmacogenomics: challenges and opportunities

21 January 2018

1 reference

The pharmacogenetics research network: from SNP discovery to clinical drug response.

21 January 2018

1 reference

Meetings that changed the world: Santa Fe 1986: Human genome baby-steps

21 January 2018

1 reference

Pharmacogenetics: from discovery to patient care

21 January 2018

1 reference

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

Role of oncoproteomics in the personalized management of cancer

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.

21 January 2018

1 reference

Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

21 January 2018

1 reference

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

21 January 2018

1 reference

Warfarin: almost 60 years old and still causing problems

21 January 2018

1 reference

Factors affecting the maintenance dose of warfarin

21 January 2018

1 reference

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

Pharmacogenetics of oral anticoagulants: a basis for dose individualization

21 January 2018

1 reference

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

21 January 2018

1 reference

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe

21 January 2018

1 reference

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

21 January 2018

1 reference

Drug-eluting stents and antiplatelet resistance

21 January 2018

1 reference

Antiplatelet drug nonresponsiveness

21 January 2018

1 reference

Aspirin and clopidogrel resistance: consideration and management

21 January 2018

1 reference

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

21 January 2018

1 reference

Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.

21 January 2018

1 reference

Determinants of the interindividual variability in response to antiplatelet drugs

21 January 2018

1 reference

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

21 January 2018

1 reference

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

21 January 2018

1 reference

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece.

21 January 2018

1 reference

Cytochrome P4502D6 genotype does not determine response to clozapine

21 January 2018

1 reference

Risperidone plasma levels, clinical response and side-effects

21 January 2018

1 reference

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

21 January 2018

1 reference

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes.

21 January 2018

1 reference

The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients

21 January 2018

1 reference

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine

21 January 2018

1 reference

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.

21 January 2018

1 reference

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics

21 January 2018

1 reference

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies

21 January 2018

1 reference

Pharmacogenetics and adverse drug reactions

21 January 2018

1 reference

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

21 January 2018

1 reference

Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients

21 January 2018

1 reference

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

21 January 2018

1 reference

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.

21 January 2018

1 reference

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

21 January 2018

1 reference

Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study

21 January 2018

1 reference

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

21 January 2018

1 reference

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

21 January 2018

1 reference

SLC6A4 variation and citalopram response

21 January 2018

1 reference

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

21 January 2018

1 reference

Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.

21 January 2018

1 reference

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

21 January 2018

1 reference

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

21 January 2018

1 reference

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

Toxicity of lithium to humans and the environment--a literature review

21 January 2018

1 reference

Lithium: a key to the genetics of bipolar disorder

21 January 2018

1 reference

Serotonin transporter gene associated with lithium prophylaxis in mood disorders.

21 January 2018

1 reference

Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.

21 January 2018

1 reference

A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder.

21 January 2018

1 reference

The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment

21 January 2018

1 reference

Trends in antimicrobial drug prescribing among office-based physicians in the United States.

21 January 2018

1 reference

Rapid molecular theranostics in infectious diseases

21 January 2018

1 reference

The impact of comparative genomics on infectious disease research

21 January 2018

1 reference

Comparative genomics of BCG vaccines by whole-genome DNA microarray

21 January 2018

1 reference

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients

21 January 2018

1 reference

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

21 January 2018

1 reference

Pharmacogenetics of tenofovir treatment

21 January 2018

1 reference

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese

21 January 2018

1 reference

Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.

21 January 2018

1 reference

Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.

21 January 2018

1 reference

Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction

21 January 2018

1 reference

Delivery of genomic medicine for common chronic adult diseases: a systematic review

21 January 2018

1 reference

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.

21 January 2018

1 reference

Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine

21 January 2018

1 reference

From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community

21 January 2018

1 reference

Pharmacogenetics education in British medical schools

21 January 2018

1 reference

Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS.

21 January 2018

1 reference

Awareness survey of parties involved in pharmacogenomics in Japan

21 January 2018

1 reference

Assessing attitudes about genetic testing as a component of continuing medical education

21 January 2018

1 reference

Economic opportunities and challenges for pharmacogenomics

21 January 2018

1 reference

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

21 January 2018

1 reference

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

21 January 2018

1 reference

Genomic and personalized medicine: foundations and applications

21 January 2018

1 reference

The role of cost-effectiveness analysis in the era of pharmacogenomics

21 January 2018

1 reference

Evolving perspectives on genetic discrimination in health insurance among health care providers

21 January 2018

1 reference

Consent and privacy in pharmacogenetic testing.

21 January 2018

1 reference

Ethical perspectives on pharmacogenomic profiling in the drug development process

21 January 2018

1 reference

Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations

21 January 2018

1 reference

Ethical and legal implications of pharmacogenomics

21 January 2018

1 reference

Ethical implications in genetic counseling and family studies of the epilepsies

21 January 2018

1 reference

Privacy issues in personalized medicine.

21 January 2018

1 reference

Tailored medicine: whom will it fit? The ethics of patient and disease stratification.

21 January 2018

1 reference

The Genetic Information Nondiscrimination Act: why your personal genetics are still vulnerable to discrimination

21 January 2018

1 reference

How will GINA influence participation in pharmacogenomics research and clinical testing?

21 January 2018

1 reference

Medicine. Racing forward: the Genomics and Personalized Medicine Act

21 January 2018

1 reference

Finding the missing heritability of complex diseases

21 January 2018

1 reference

Mitochondrial pharmacogenomics: barcode for antibiotic therapy.

21 January 2018

1 reference

Different nucleotide changes in the large rRNA gene of the mitochondrial DNA confer chloramphenicol resistance on two human cell lines

21 January 2018

1 reference

Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA.

21 January 2018

1 reference

Erythromycin as a potential precipitating agent in the onset of Leber's hereditary optic neuropathy.

21 January 2018

1 reference

Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation

21 January 2018

1 reference

The Personalized Medicine Coalition: goals and strategies

21 January 2018

1 reference

Personalized medicine for the brain: a call for action.

21 January 2018

1 reference

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

21 January 2018

1 reference

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea

21 January 2018

1 reference

Insurance coverage for pharmacogenomic testing in the USA

21 January 2018

1 reference

A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.10.97

1 reference

31 July 2017

1 reference